New COVID-19 Monoclonal Antibody Data Could Shift Clinical Practice
New data from phase 3 trials of monoclonal antibodies for patients with recent COVID-19 diagnoses, or at high risk for SARS-CoV-2 infection, could move the needle on clinician acceptance of the treatments, experts say. Two monoclonal antibody formulations, Eli Lilly’s bamlanivimab and Regeneron’s cocktail of two antibodies, casirivimab and imdevimab, received emergency use authorizations from […] Read More